Clinical trialPhase 3Suspended
L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)
L-Carnitine in the Palliative Treatment of Advanced Pancreatic Cancer (CARPAN): a Prospective, Randomised, Placebo Controlled, Double Blinded, Multicentre Trial
- Outcome
- Stopped earlyafter interims analysis standard errors for inflammatory and nutritional markers varied widely, that the power calculation required unattainable goals (Other)
- Phase
- Phase 3
- Status
- Suspended
- Study type
- Interventional
- Start
- June 2006
- Expected end
- July 2010
- Enrollment
- 72 participants
- Sites
- 1
- Primary outcomes
- TNF-alpha
- Sponsor
- Other
- Results posted
- No
- Last update
- 7 April 2011
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, UICC Stage IV .
Detailed description public domain (ClinicalTrials.gov)
Pancreatic cancer has the lowest 5-year survival rate of any cancer and ranks as the fourth leading cause of cancer death world wide. Several metabolic changes are present in the whole body in case of cancer so the investigators conducted a placebo controlled, double blinded, randomized, prospective and multicentre study to investigate, whether L-Carnitine supplementation may have an impact on malnutrition, cancer cachexia and cancer related fatigue in advanced pancreatic cancer. Study drug: L-Carnitine 4g per day (vers) Placebo Study design: A multi-centre, double blind, and placebo-controlled, randomised, parallel group study Patient population: Patients with advanced pancreatic carcinoma Number of patients: Total of 90 patients in two equal groups number of centres: 4 (Greifswald, Magdeburg, Berlin,Heidelberg,all Germany) Duration of dosing: 12 weeks
Papers 1
- Registry-listed results paperL-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. DOI 10.1186/1475-2891-11-52↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.